Seres Therapeutics to Host Second Quarter 2017 Financial Results & Operational Progress Conference Call & Webcast on August 3...
July 27 2017 - 6:05AM
Business Wire
Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that
management will host a conference call and live audio webcast on
August 3, 2017 at 8:00 a.m. ET to discuss second
quarter 2017 results and provide a general business update.
To access the conference call, please dial 844-277-9450
(domestic) or 336-525-7139 (international) and reference the
conference ID number 62118608. To join the live webcast, please
visit the “Investors and Media” section of the Seres website
at www.serestherapeutics.com.
A webcast replay will be available on the Seres website
beginning approximately two hours after the event and will be
archived for approximately 21 days.
About Seres TherapeuticsSeres Therapeutics,
Inc. is a leading microbiome therapeutics platform company
developing a novel class of biological drugs that are designed to
treat disease by restoring the function of a dysbiotic microbiome,
where the natural state of bacterial diversity and function is
imbalanced. Seres’ lead program, SER-109, has obtained Breakthrough
and Orphan Drug designations from the US Food and Drug
Administration and is in Phase 3 development for multiply recurrent
C. difficile infection. Seres’ clinical candidate SER-287 is being
evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis. Seres is also developing SER-262, the first
ever synthetic microbiome therapeutic candidate, in a Phase 1b
study in patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com. Follow us
on Twitter @SeresTx.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170727005125/en/
IR or PR Contact:Seres Therapeutics, Inc.Carlo Tanzi,
Ph.D., 617-203-3467Head of Investor Relations and Corporate
Communicationsctanzi@serestherapeutics.com
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From Apr 2024 to May 2024
Seres Therapeutics (NASDAQ:MCRB)
Historical Stock Chart
From May 2023 to May 2024